These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35532193)

  • 21. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
    Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
    J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of Cluster Analysis of Time Evolution for Magnetic Resonance Imaging -Derived Oxygen Extraction Fraction Mapping: A Promising Strategy for the Genetic Profile Prediction and Grading of Glioma.
    Shen N; Zhang S; Cho J; Li S; Zhang J; Xie Y; Wang Y; Zhu W
    Front Neurosci; 2021; 15():736891. PubMed ID: 34671241
    [No Abstract]   [Full Text] [Related]  

  • 24. Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis.
    Liang J; Liu D; Gao P; Zhang D; Chen H; Shi C; Luo L
    Acad Radiol; 2018 Mar; 25(3):338-348. PubMed ID: 29223713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
    Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
    AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations.
    Siakallis L; Topriceanu CC; Panovska-Griffiths J; Bisdas S
    Neuroradiology; 2023 Jul; 65(7):1111-1126. PubMed ID: 37173578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glioma grading using multiparametric MRI: head-to-head comparison among dynamic susceptibility contrast, dynamic contrast-enhancement, diffusion-weighted images, and MR spectroscopy.
    Seo M; Choi Y; Soo Lee Y; Ahn KJ; Kim BS; Park JS; Jeon SS
    Eur J Radiol; 2023 Aug; 165():110888. PubMed ID: 37257338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
    Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
    J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI.
    Choi HS; Kim AH; Ahn SS; Shin NY; Kim J; Lee SK
    Korean J Radiol; 2013; 14(3):487-92. PubMed ID: 23690718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The value of DCE-MRI in predicting IDH gene mutation of high-grade gliomas].
    Lu HT; Xing W; Zhang YW; Qin HP; Wu RH; Ding JL
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(39):3105-3109. PubMed ID: 31648456
    [No Abstract]   [Full Text] [Related]  

  • 31. Magnetic Resonance Imaging Parameters for Noninvasive Prediction of Epidermal Growth Factor Receptor Amplification in Isocitrate Dehydrogenase-Wild-Type Lower-Grade Gliomas: A Multicenter Study.
    Park YW; Park JE; Ahn SS; Kim EH; Kang SG; Chang JH; Kim SH; Choi SH; Kim HS; Lee SK
    Neurosurgery; 2021 Jul; 89(2):257-265. PubMed ID: 33913501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI.
    Lin Y; Xing Z; She D; Yang X; Zheng Y; Xiao Z; Wang X; Cao D
    Neuroradiology; 2017 Jun; 59(6):555-562. PubMed ID: 28474187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
    Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
    J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.
    Tatekawa H; Hagiwara A; Uetani H; Yao J; Oughourlian TC; Bahri S; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM
    J Neurooncol; 2020 Sep; 149(2):337-346. PubMed ID: 32929644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Volume-based histogram analysis of dynamic contrast-enhanced MRI for estimation of gliomas IDH1 mutation status.
    Hu Y; Zhang N; Yu MH; Zhou XJ; Ge M; Shen DD; Hua Y; Shi JL; Jia ZZ
    Eur J Radiol; 2020 Oct; 131():109247. PubMed ID: 32891974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perfusion parameters derived from MRI for preoperative prediction of IDH mutation and MGMT promoter methylation status in glioblastomas.
    Lu J; Li X; Li H
    Magn Reson Imaging; 2021 Nov; 83():189-195. PubMed ID: 34506909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mean apparent propagator-MRI in evaluation of glioma grade, cellular proliferation, and IDH-1 gene mutation status.
    Sun Y; Su C; Deng K; Hu X; Xue Y; Jiang R
    Eur Radiol; 2022 Jun; 32(6):3744-3754. PubMed ID: 35076759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.